Diagnostic Tools for Calculation of Glaucoma Risk

Survey of Ophthalmology

Volumn 53, Issue 6 SUPPL., 2008, Pages

  Mansberger, Steve L ^a   Medeiros, Felipe A ^b   Gordon, Mae ^c  

^a DEVERS EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Early Manifest Glaucoma trial; European Glaucoma Prevention study; glaucoma; ocular hypertension; Ocular Hypertension Treatment Study; risk assessment; risk calculator

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEALTH CARE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL DECISION MAKING; MONOTHERAPY; OPEN ANGLE GLAUCOMA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TRABECULOPLASTY; VISUAL FIELD;

DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DISEASE PROGRESSION; GLAUCOMA, OPEN-ANGLE; HUMANS; MODELS, STATISTICAL; OCULAR HYPERTENSION; RISK ASSESSMENT; RISK FACTORS;

EID: 56449085490     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2008.08.005     Document Type: Article

References (14)

1. ___: A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 274 (1995) 1591-1598
2. Coleman A.L., Gordon M.O., Beiser J.A., et al. Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study. Am J Ophthalmol 138 (2004) 684-685
3. Gordon M.O., Torri V., Miglior S., et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 114 (2007) 10-19
4. Hosmer D.W., and Lemeshow S. Applied survival analysis: regression modeling of time to event data, Vol 13 (1999), Wiley, New York p 386
5. Institute of Medicine (U.S.). Committee on Quality of Health Care in America: Crossing the quality chasm: a new health system for the 21st century (2001), National Academy Press, Washington, DC p 337
6. Kymes S.M., Kass M.A., Anderson D.R., et al. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 141 (2006) 997-1008
7. Leske M.C., Heijl A., Hussein M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121 (2003) 48-56
8. Leske M.C., Heijl A., Hyman L., et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology 106 (1999) 2144-2153
9. Leske M.C., Heijl A., Hyman L., et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 114 (2007) 1965-1972
10. Liu J., Hong Y., D'Agostino R.B., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291 (2004) 2591-2599
11. Mansberger S.L., and Cioffi G.A. The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator. J Glaucoma 15 (2006) 426-431
12. Medeiros F.A., Weinreb R.N., Sample P.A., et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol 123 (2005) 1351-1360
13. Tielsch J.M., Katz J., Singh K., et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 134 (1991) 1102-1110
14. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847